NovaKonexus™ is revolutionizing healthcare and rehabilitation by integrating advanced technologies, including AI, robotics, and digital health solutions. Guided by the “Innovation for Life mission,” we bridge cutting-edge research, clinical implementation, and scalable commercialization to deliver transformative solutions addressing critical needs in neurorehabilitation, orthopaedics, and geriatrics.

Our innovations—such as AI-powered exoskeletons, neurorehabilitation devices, wearable sensors, and telerehabilitation platforms—empower patients to regain mobility, independence and quality of life. Leveraging strategic partnerships with Germany’s Michels Kliniken GmbH & Co. KG, Singapore’s Robotimize Group, and Canada’s University Health Network (UHN), we ensure rigorous validation, seamless clinical integration, and global distribution of our technologies.

Through Switzerland’s MotusAcademy, we educate healthcare professionals and advocate for adopting advanced rehabilitation technologies, driving policy change and industry-wide transformation. Supported by an expansive ecosystem of academic, clinical, and industry partners, NovaKonexus™ is positioned as a global leader in delivering innovative, patient-centred healthcare solutions.

With a focus on impactful collaboration and sustainable innovation, NovaKonexus™ is shaping the future of rehabilitation, creating measurable outcomes for patients, and unlocking significant value for stakeholders worldwide.

‍

UNMET NEED

The global healthcare sector urgently needs innovative solutions in rehabilitation and geriatric care. With the rapidly ageing population—projected to exceed 2.1 billion people aged 60 and older by 2050—there is a pressing demand for advanced technologies supporting independence, mobility, and recovery. Furthermore, the rising prevalence of neurological disorders such as stroke, spinal cord injuries, and neurodegenerative diseases has created an unprecedented strain on healthcare systems, leaving millions without adequate access to effective rehabilitation.

Traditional rehabilitation approaches are resource-intensive, location-dependent, and often unable to meet the diverse needs of patients, particularly in underserved or remote areas. This gap is exacerbated by the lack of scalable, technology-driven solutions that deliver personalized, adaptive, and cost-effective care. The global neurorehabilitation devices market, valued at approximately USD 2 billion in 2023, continues to grow, yet many patients remain unable to access these life-changing innovations.

NovaKonexus™ addresses these unmet needs by delivering clinically validated, AI-powered robotics, wearable sensors, and telerehabilitation platforms. Our solutions bridge the gap between research and practical application, empowering patients with personalized care while reducing systemic burdens. By transforming the rehabilitation landscape, NovaKonexus™ ensures equitable access to life-enhancing technologies, improving patient outcomes worldwide.

‍

‍INNOVATION

‍
NovaKonexus™ is pioneering transformative innovations in rehabilitation and healthcare, leveraging advanced technologies to address critical needs in neurorehabilitation, orthopaedics, and geriatrics. Our solutions integrate artificial intelligence, robotics, wearable sensors, and digital health platforms, ensuring personalized, scalable, and effective care for patients worldwide.

1.    AI-Powered Exoskeletons: Advanced robotic systems designed to restore mobility for patients with neurological impairments. These devices combine AI and biomechanics to adapt to individual needs, enhancing gait recovery and improving independence.

2.    Neurorehabilitation Devices: Technologies incorporating neurostimulation and brain-computer interfaces to foster neuroplasticity, accelerate recovery, and enable patients to regain lost functions after strokes or brain injuries.

3.    Digital Health Platforms: Telerehabilitation tools that provide remote monitoring, personalized therapy plans, and real-time communication between patients and clinicians. These platforms ensure access to high-quality care, especially for underserved populations.

4.    Wearable Sensors: Intelligent devices that track patient progress, monitor vital signs, and deliver actionable insights for clinicians to optimize treatment plans.

5.    Virtual Reality (VR) and Gamified Therapies: Immersive experiences to engage patients in rehabilitation, promoting adherence and improved outcomes.

By seamlessly integrating these innovations with clinical expertise and scalable distribution, NovaKonexus™ empowers patients to regain mobility, independence, and quality of life, while transforming global rehabilitation practices.

‍

APPLICATION/UTILITIES

‍
NovaKonexus™ technologies are redefining how rehabilitation and healthcare are delivered, ensuring advanced, accessible and scalable solutions that meet the needs of diverse patient populations. By integrating artificial intelligence, robotics, and digital platforms, our innovations offer applications and utilities across various domains:

1.    Neurorehabilitation: AI-powered exoskeletons and neurostimulation devices aid in restoring mobility, fostering neuroplasticity, and improving recovery for patients with stroke, spinal cord injuries, and traumatic brain injuries. These technologies enable targeted, adaptive therapies that accelerate progress and enhance independence.

2.    Orthopaedic Recovery: Robotics and wearable sensors optimize post-surgical rehabilitation for musculoskeletal injuries, delivering personalised therapy and real-time monitoring to support effective recovery.

3.    Geriatric Care: Digital health platforms and wearable devices empower older adults to maintain mobility and manage age-related conditions, offering remote monitoring and adaptive care to improve quality of life.

4.    Telerehabilitation: Remote access to therapy via virtual platforms ensures continuity of care for underserved or geographically isolated populations. Real-time clinician-patient communication and data-driven insights enhance treatment precision and patient outcomes.

5.    Education and Training: MotusAcademy provides clinicians with training and certification programs, promoting the effective adoption of NovaKonexus™ technologies in clinical settings.

With applications spanning neurorehabilitation, orthopaedics, geriatrics, and beyond, NovaKonexus™ delivers transformative solutions to enhance patient care and advance global healthcare standards.

‍

INVESTMENT/INVESTMENT OBJECTIVES

‍
US$5M- US$10M required to: 

NovaKonexus™ seeks an investment of USD $5–10 million to advance its mission of transforming global healthcare and rehabilitation through cutting-edge technologies. This investment will enable the development, validation, and commercialization of innovative solutions, positioning NovaKonexus™ as a global leader in neurorehabilitation, orthopaedics, and geriatric care.

Objectives for the Investment

1.    Accelerate R&D and Product Development: The investment will support the refinement and advancement of AI-powered robotics, neurostimulation devices, wearable sensors and digital health platforms. These resources will ensure the delivery of clinically validated, market-ready solutions that address critical unmet needs in healthcare.

2.    Expand Clinical Trials and Validation: Resources will facilitate robust clinical trials in partnership with Michels Kliniken and UHN, ensuring product efficacy, safety, and compliance with international regulatory standards.

3.     Scale Manufacturing and Global Distribution: The investment will enable strategic partnerships with Robotimize Group and global distributors, streamlining production processes and accelerating market entry in North America, Europe, and Asia-Pacific.

4.    Advance Telerehabilitation and Patient Access: Funds will support the rollout of digital health platforms, ensuring equitable access to high-quality rehabilitation care, particularly for underserved populations.

By fulfilling these objectives, the investment will drive innovation, expand global reach, and deliver transformative healthcare solutions to enhance patient outcomes worldwide.

COMPETITIVE ADVANTAGE

NovaKonexus™ stands out as a pioneer in the healthcare and rehabilitation sector. It leverages cutting-edge technologies and a robust ecosystem of strategic partnerships to deliver unparalleled value.

1.    Innovative Technologies: NovaKonexus™integrates AI, robotics, neurostimulation, and digital health platforms to develop advanced rehabilitation solutions. Our AI-powered exoskeletons, wearable sensors, and telerehabilitation platforms offer adaptive, patient-centred therapies that accelerate recovery and improve outcomes.

2.    Validated Clinical Expertise: Collaborations with world-class institutions such as Michels Kliniken and the University Health Network (UHN) ensure rigorous clinical validation of all products. This approach guarantees safety, efficacy, and alignment with the highest healthcare standards.

3.    Global Distribution Network: Partnerships with Robotimize Group and other established distributors enable efficient global market entry. Our solutions are designed for seamless scalability, meeting the growing demand for rehabilitation technologies across North America, Europe, and Asia-Pacific.

4.    Patient-Centred Innovation: Unlike competitors, NovaKonexus™ focuses on restoring patient independence, dignity, and quality of life through personalized care solutions.

5.    Integrated Education and Advocacy: Through MotusAcademy, we empower healthcare professionals with training and certifications to ensure the effective adoption of our technologies, driving industry-wide transformation.

NovaKonexus™ combines technological excellence, clinical validation, and global reach, establishing itself as a leader in transformative healthcare solutions and setting new benchmarks in rehabilitation innovation.

‍

‍MARKET SIZE

‍
NovaKonexus™ operates within two rapidly expanding markets: neurorehabilitation devices and geriatric care services.

‍

Neurorehabilitation Devices Market
The global neurorehabilitation devices market was valued at approximately USD 2.0 billion in 2023 and is projected to grow at a compound annual growth rate(CAGR) of 13.9% from 2024 to 2030, reaching an estimated USD 6.1 billion by 2030.

[Source: https://www.grandviewresearch.com/industry-analysis/neurorehabilitation-devices-market]

Geriatric Care Services Market
The global geriatric care services market was valued at around USD 1.45 trillion in 2023 and is expected to grow at a CAGR of 7.8% between 2024 and2032, reaching approximately USD 2.89 trillion by 2032. [Source: https://www.gminsights.com/industry-analysis/geriatric-care-services-market-report]  

‍

Market Drivers

Aging Population: the increasing number of individuals aged 60 and older is driving for demand for advanced rehabilitation and geriatric care solutions.

Neurological Disorders: a rise in conditions such as stroke, Parkinson's disease and spinal cord injuries necessitates innovative neurorehabilitation devices.

‍

‍NovaKonexus™'s Position
By developing cutting-edge technologies in neurorehabilitation and geriatric care, NovaKonexus™ is strategically positioned to capture significant market share in these expanding industries.

IP PORTFOLIO:

NovaKonexus™ is built on a cutting-edge intellectual property (IP) foundation developed in collaboration with leading research institutions and healthcare innovators. A significant milestone in our IP strategy is the signed Term Sheet with  University Health Network (UHN), which formalizes the commercialization of relevant IP through NovaKonexus™. This agreement provides access to groundbreaking technologies rigorously tested and clinically validated within UHN’s world-class research ecosystem.

‍

Key Areas of IP 

‍1.     AI-Powered Exoskeleton Technologies

·      Innovations in adaptive robotics for neurorehabilitation and mobility restoration. 

·      Enhanced by AI algorithms for personalized therapy based on patient-specific needs.

 2.     Neurostimulation and Brain-Computer Interfaces

·      Patented systems fostering neuroplasticity and accelerating recovery.

·      Advanced integration of neural feedback for precise therapeutic interventions.

 3.     Digital Health Platform

·      IP related to telerehabilitation, remote monitoring, and real-time data analytics. 

·      Ensures continuity of care and accessibility for underserved populations.

 4.     Wearable Sensors

·      Innovations in real-time tracking of patient progress and vital signs.  

·      Integrated feedback loops for clinicians to refine treatment plans.

‍

NovaKonexus™’s exclusive licensing agreement with UHN positions the company to lead the commercialization of state-of-the-art rehabilitation technologies, creating a robust competitive advantage in the global healthcare market.

‍

CURRENT READINESS LEVEL

NovaKonexus™ is currently in the product development phase, with multiple technologies advancing towards clinical validation. Key innovations undergo rigorous design and pre-clinical testing to ensure safety, efficacy, and readiness for real-world applications.

‍

1.   Pre-ClinicalTrial Phase

 ·      AI-PoweredExoskeletons: Early prototypes will go into the pre-clinical testing phase early 2025, focusing on restoring mobility for patients with neurological impairments. This involves validating safety and functional performance in controlled environments.

·      Neurostimulation Devices and Brain-Computer Interfaces: Cutting-edge prototypes are being evaluated for their ability to foster neuroplasticity and accelerate recovery, ensuring robust results prior to clinical trials.

‍2.   Expected Clinical Trials

 ·      Once prototypes are finalized, clinical trials for NovaKonexus™’s flagship technologies are anticipated to begin in Q1/Q2 2025. These trials will be conducted in collaboration with leading institutions such as Michels Kliniken and UHN, ensuring the highest validation standards.

3. Digital Health Platforms

·      Supporting telerehabilitation tools, which integrate remote monitoring and adaptive care solutions to complement physical devices, are at an advanced development stage.

NovaKonexus™is progressing steadily towards clinical readiness, ensuring its innovative solutions are primed for impactful deployment in global healthcare settings.

‍

MANAGEMENT TEAM

Zen Koh, CEO*

Zen Koh is a distinguished figure in the field of rehabilitation technology, bringing over two decades of experience to his role as Entrepreneur-in-Residence (EIR) at UHN and incoming CEO of NovaKonexus™. He is renowned for co-founding Fourier Intelligence, where he serves as Global CEO, leading the company to prominence in developing advanced exoskeletons and rehabilitation robotics. Under his leadership, Fourier Intelligence secured approximately USD 100 million in Series C and D funding from prominent investors, including Saudi Aramco's Prosperity7 Ventures and SoftBank Vision Fund.

Zen's career is marked by significant contributions to medical technology and rehabilitation services. He has held pivotal roles, such as Managing Director of Hocoma's Asia Pacific Hub, where he was instrumental in expanding the market for advanced rehabilitation robotics.

In recognition of his impact on the MedTech industry, Zen was named among the"40 under 40 Future Most Influential Industry Leaders in MedTech by MD+DI in 2012.

Beyond his corporate endeavors, Zen is the Founder and Executive Director of MotusAcademy, a Swiss-based association dedicated to advancing education in robotics and healthcare technologies.

He also serves as the President and Ambassador of the International Industry Society of Advanced Rehabilitation Technology (IISART), reflecting his commitment to global collaboration in the field.

Zen's academic background includes a Master of Engineering from the National University of Singapore and a Bachelor of Engineering with Honours from the University of Strathclyde.

His extensive experience and visionary leadership uniquely position him to steer NovaKonexus™ toward achieving its mission of transforming global healthcare through innovative rehabilitation technologies.

Derived from: 

Source: https://2023.rehabweek.org/assets/2022-23_Zen-KOH_Biography.pdf)

Source: https://www.dellaleaders.com/profile/zen-koh/

‍

‍SCIENTIFIC FOUNDER(S)/INVENTOR(S):

‍
Dr. Milos R. Popovic is a leading neurorehabilitation and functional electrical stimulation (FES) expert. He is Director of The KITE Research Institute at the Toronto Rehabilitation Institute, University Health Network (UHN) as well as Director and Professor at the Institute of Biomedical Engineering, University of Toronto.

Born in Belgrade, Serbia, Professor Popovic earned his Dipl. Electrical Engineering degree from the University of Belgrade in 1990. He then pursued his Ph.D. in Mechanical Engineering at the University of Toronto, completing it in 1996.

In 2001, he established the Rehabilitation Engineering Laboratory at the Toronto Rehabilitation Institute, focusing on developing advanced neuroprostheses and rehabilitation technologies. His pioneering work in FES has significantly advanced treatments for stroke and spinal cord injury patients, enhancing their motor functions and quality of life.

Dr. Popovic co-founded MyndTec, a medical technology company specializing in FES therapies for paralysis resulting from stroke and spinal cord injuries. He also played a pivotal role in establishing the Centre for Research in Advanced Neural Implant Applications (CRANIA) at UHN and the University of Toronto, promoting innovation in neurotechnologies.

Throughout his career, he has received numerous accolades, including the Engineering Medal for Research and Development from the Professional Engineers of Ontario in 2008 and the Jonas Salk Award from March of Dimes Canada in 2018.

Dr. Popovic's extensive research has been widely published, with a significant number of citations reflecting his impact on the field.

His dedication to advancing neurorehabilitation continues to influence both academic research and clinical practice globally.

Source: https://www.uhnresearch.ca/researcher/milos-popovic

‍